Sign In
9 Mar 2021 07:00
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity MGC Pharmaceuticals Limited |
ABN 30 116 800 269 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of Director | Stephen Barry Parker |
Date of last notice | 13 March 2019 |
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest | Indirect |
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.
| Held through a UK Individual Savings Account ("ISA")
Registered Holder is Barclays Bank PLC |
Date of change | 5 March 2021 |
No. of securities held prior to change | Nil |
Class | Ordinary shares |
Number acquired | 282,316 |
Number disposed | - |
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation
| £9,999.99 |
No. of securities held after change | 282,316 ordinary shares |
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | On-market trade |
Part 2 - Change of director's interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract | N/A |
Nature of interest | |
Name of registered holder (if issued securities)
| |
Date of change | |
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
| |
Interest acquired | |
Interest disposed | |
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
| |
Interest after change |
Part 3 - +Closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
If so, was prior written clearance provided to allow the trade to proceed during this period? |
|
If prior written clearance was provided, on what date was this provided? |
|
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity MGC Pharmaceuticals Limited |
ABN 30 116 800 269 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of Director | Brett Anthony Mitchell |
Date of last notice | 12 August 2020 |
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest | Indirect |
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.
| Brett and Michelle Mitchell Trustee Brett and Michelle Mitchell Trustee |
Date of change | 5 March 2021 |
No. of securities held prior to change | Brett and Michelle Mitchell 22,264,444 Fully Paid Ordinary Shares 3,750,000 Performance Rights 277,777 Listed Options exercisable at $0.045 each expiring 31 August 2021
Brett and Michelle Mitchell 8,140,560 Fully Paid Ordinary Shares 3,750,000 Performance Rights 277,777 Listed Options exercisable at $0.045 each expiring 31 August 2021
Chieftain Securities Pty Ltd 5,000,000 Unlisted Options exercisable at $0.15 expiring 30 June 2021 1,500,000 Unlisted Options exercisable at $0.05 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at $0.06 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at $0.07 expiring 31 August 2023 |
Class | Performance Rights |
Number acquired | Nil |
Number disposed | 2,500,000 |
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation
| Nil - Cancellation of performance rights |
No. of securities held after change | Brett and Michelle Mitchell 22,264,444 Fully Paid Ordinary Shares 2,500,000 Performance Rights 277,777 Listed Options exercisable at $0.045 each expiring 31 August 2021
Brett and Michelle Mitchell 8,140,560 Fully Paid Ordinary Shares 2,500,000 Performance Rights 277,777 Listed Options exercisable at $0.045 each expiring 31 August 2021
Chieftain Securities Pty Ltd 5,000,000 Unlisted Options exercisable at $0.15 expiring 30 June 2021 1,500,000 Unlisted Options exercisable at $0.05 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at $0.06 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at $0.07 expiring 31 August 2023 |
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Cancellation of performance shares due to performance conditions lapsing. |
Part 2 - Change of director's interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract | N/A |
Nature of interest | |
Name of registered holder (if issued securities)
| |
Date of change | |
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
| |
Interest acquired | |
Interest disposed | |
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
| |
Interest after change |
Part 3 - +Closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
If so, was prior written clearance provided to allow the trade to proceed during this period? |
|
If prior written clearance was provided, on what date was this provided? |
|
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity MGC Pharmaceuticals Limited |
ABN 30 116 800 269 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of Director | Roby Reuven Zomer |
Date of last notice | 12 August 2020 |
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest | Indirect |
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.
| Chitta Lu Limited (Director and sole shareholder)
|
Date of change | 5 March 2021 |
No. of securities held prior to change | Chitta Lu Limited 3,000,001 Fully Paid Ordinary Shares 7,500,000 Performance Rights
HSBC Custody Nominees (Australia) Limited 30,000,000 Fully Paid Ordinary Shares
|
Class | Performance Rights
|
Number acquired | Nil |
Number disposed | 2,500,000 Performance Rights |
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation
| Non-cash - forfeited due to not meeting performance conditions. |
No. of securities held after change | Chitta Lu Limited 3,000,001 Fully Paid Ordinary Shares 5,000,000 Performance Rights
HSBC Custody Nominees (Australia) Limited 30,000,000 Fully Paid Ordinary Shares
|
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Cancellation of performance rights due to performance conditions lapsing |
Part 2 - Change of director's interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract | N/A |
Nature of interest | |
Name of registered holder (if issued securities)
| |
Date of change | |
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
| |
Interest acquired | |
Interest disposed | |
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
| |
Interest after change |
Part 3 - +Closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | N/A |
If so, was prior written clearance provided to allow the trade to proceed during this period? |
|
If prior written clearance was provided, on what date was this provided? |
|
Follow the stocks
